BML-190

Iz Wikipedije, slobodne enciklopedije
BML-190
(IUPAC) ime
2-[1-(4-hlorobenzoil)-5-metoksi-2-metilindol-3-il]-1-morfolin-4-iletanon
Klinički podaci
Identifikatori
CAS broj 2854-32-2
ATC kod nije dodeljen
PubChem[1][2] 2415
ChemSpider[3] 2321
Hemijski podaci
Formula C23H23ClN2O4 
Mol. masa 426,892
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća ?
Pravni status

BML-190 (Indometacin morfolinilamid) je lek koji se koristi u naučnim istraživanjima. On deluje kao selektivan inverzni agonist CB2 receptora.[4] BML-190 je strukturni analog NSAID indometacina koji ima sasvim različita biološka svojstava.[5] Neki izvori osporavaju aktivnost ovoj jedinjenja, i navode da je CB2 agonist umesto inverznog agonista.[6][7] Razlog za to može da bude greška u klasifikaciji, ili alternativno moguće je da ovaj materijal proizvodi različite efekte u različitim tkivima i eksperimentalnim uslovima.

Reference[uredi - уреди | uredi izvor]

  1. Li Q, Cheng T, Wang Y, Bryant SH (2010). "PubChem as a public resource for drug discovery.". Drug Discov Today 15 (23-24): 1052–7. PMID 20970519. doi:10.1016/j.drudis.2010.10.003.  edit
  2. Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). "Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities". Annual Reports in Computational Chemistry 4: 217–241. doi:10.1016/S1574-1400(08)00012-1. 
  3. Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). "Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining". J Cheminform 2 (1): 3. PMID 20331846. doi:10.1186/1758-2946-2-3.  edit
  4. New, DC; Wong, YH (2003). "BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates". FEBS Letters 536 (1–3): 157–60. PMID 12586356. doi:10.1016/S0014-5793(03)00048-6. 
  5. Klegeris, A; Bissonnette, CJ; McGeer, PL (2003). "Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor". British Journal of Pharmacology 139 (4): 775–86. PMC 1573900. PMID 12813001. doi:10.1038/sj.bjp.0705304. 
  6. Melck, D; De Petrocellis, L; Orlando, P; Bisogno, T; Laezza, C; Bifulco, M; Di Marzo, V (2000). "Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation". Endocrinology 141 (1): 118–26. PMID 10614630. doi:10.1210/en.141.1.118. 
  7. Scutt, A; Williamson, EM (2007). "Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors". Calcified tissue international 80 (1): 50–9. PMID 17205329. doi:10.1007/s00223-006-0171-7. 

Spoljašnje veze[uredi - уреди | uredi izvor]